Clinical Observation of Shengxuening Tablets Reducing the Risk of Microinflammation in Maintenance Ho-modialys with Renal Anemia
10.6039/j.issn.1001-0408.2016.08.27
- VernacularTitle:生血宁片在维持性血液透析肾性贫血治疗中减少微炎症风险的临床观察
- Author:
Yongbing LIU
;
Dajun HU
- Publication Type:Journal Article
- Keywords:
Shengxuening tablets;
Renal anemia;
Microinflammation;
Erythropoietin;
Maintenance hornodialysis
- From:
China Pharmacy
2016;27(8):1096-1098
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy of Shengxuening tablets reducing the risk of microinflammation in maintenance hemodialysis(MHD)patients with renal anemia. METHODS:60 MHD patients were randomly divided into observa-tion group and control group with 30 cases in each group. The total dialysis times of all the patients were 12 h every week at blood flow of 200-250 ml/min and dialysis flow of 500 ml/min. Both groups received routine treatment;observation group was additional-ly given Shengxuening tablets orally 1.0 g,tid;control group was given ferrous succinate 0.2 g,tid,orally;both groups were giv-en subcutaneous injection of erythropoietin (EPO),10 000 IU/time,once a week;treatment for all of the patients lasted for 3 months. The fasting venous blood sample were collected at the beginning of treatment and in the morning every one months. The levels of hypersensitive C-reactive protein(hs-CRP),tumor necrosis factor α(TNF-α),IL-6,hemoglobin(Hb),and hematocrit (Hct)were detected. RESULTS:After 3 months of treatment,total effective rate of 2 groups were 90.00%,the levels of hs-CRP、TNF-α、IL-6 in observation group were much lower than that before treatment and control group after treatment,with statistical sig-nificance(P<0.05 or P<0.01). No severe ADR was found in 2 groups,and the incidence of ADR in observation group(6.67%) was significantly lower than in control group (13.33%),with statistical significance (P<0.05). CONCLUSIONS:Shengxuening tablets have good curative effect,and they can reduce the risk of microinflammation due to the long-term use of EPO and chalybeate.
